HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury

B. K. Harvey, C. F. Chang, Y. H. Chiang, W. J. Bowers, M. Morales, B. J. Hoffer, Y. Wang, H. J. Federoff

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Direct intracerebral administration of glial cell line-derived neurotrophic factor (GDNF) is neuroprotective against ischemia-induced cerebral injury. Utilizing viral vectors to deliver and express therapeutic genes presents an opportunity to produce GDNF within localized regions of an evolving infarct. We investigated whether a herpes simplex virus (HSV) amplicon-based vector encoding GDNF (HSVgdnf) would protect neurons against ischemic injury. In primary cortical cultures HSVgdnf reduced oxidant-induced injury compared to the control vector HSVlac. To test protective effects in vivo, HSVgdnf or HSVlac was injected into the cerebral cortex 4 days prior to, or 3 days, after a 60-min unilateral occlusion of the middle cerebral artery. Control stroke animals developed bradykinesia and motor asymmetry; pretreatment with HSVgdnf significantly reduced such motor deficits. Animals receiving HSVlac or HSVgdnf after the ischemic insult did not exhibit any behavioral improvement. Histological analyses performed 1 month after stroke revealed a reduction in ischemic tissue loss in rats pretreated with HSVgdnf. Similarly, these animals exhibited less immunostaining for glial fibrillary acidic protein and the apoptotic marker caspase-3. Taken together, our data indicate that HSVgdnf pretreatment provides protection against cerebral ischemia and supports the utilization of the HSV amplicon for therapeutic delivery of trophic factors to the CNS.

Original languageEnglish
Pages (from-to)47-55
Number of pages9
JournalExperimental Neurology
Volume183
Issue number1
DOIs
Publication statusPublished - Sep 1 2003
Externally publishedYes

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Simplexvirus
Brain Ischemia
Wounds and Injuries
Stroke
Hypokinesia
Middle Cerebral Artery Infarction
Glial Fibrillary Acidic Protein
Oxidants
Caspase 3
Cerebral Cortex
Neurons
Therapeutics
Genes

Keywords

  • Amplicon
  • GDNF
  • Gene therapy
  • Herpes simplex
  • Ischemia
  • Stroke

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. / Harvey, B. K.; Chang, C. F.; Chiang, Y. H.; Bowers, W. J.; Morales, M.; Hoffer, B. J.; Wang, Y.; Federoff, H. J.

In: Experimental Neurology, Vol. 183, No. 1, 01.09.2003, p. 47-55.

Research output: Contribution to journalArticle

Harvey, B. K. ; Chang, C. F. ; Chiang, Y. H. ; Bowers, W. J. ; Morales, M. ; Hoffer, B. J. ; Wang, Y. ; Federoff, H. J. / HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. In: Experimental Neurology. 2003 ; Vol. 183, No. 1. pp. 47-55.
@article{98faba8a394b4e6594883a515e1c7296,
title = "HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury",
abstract = "Direct intracerebral administration of glial cell line-derived neurotrophic factor (GDNF) is neuroprotective against ischemia-induced cerebral injury. Utilizing viral vectors to deliver and express therapeutic genes presents an opportunity to produce GDNF within localized regions of an evolving infarct. We investigated whether a herpes simplex virus (HSV) amplicon-based vector encoding GDNF (HSVgdnf) would protect neurons against ischemic injury. In primary cortical cultures HSVgdnf reduced oxidant-induced injury compared to the control vector HSVlac. To test protective effects in vivo, HSVgdnf or HSVlac was injected into the cerebral cortex 4 days prior to, or 3 days, after a 60-min unilateral occlusion of the middle cerebral artery. Control stroke animals developed bradykinesia and motor asymmetry; pretreatment with HSVgdnf significantly reduced such motor deficits. Animals receiving HSVlac or HSVgdnf after the ischemic insult did not exhibit any behavioral improvement. Histological analyses performed 1 month after stroke revealed a reduction in ischemic tissue loss in rats pretreated with HSVgdnf. Similarly, these animals exhibited less immunostaining for glial fibrillary acidic protein and the apoptotic marker caspase-3. Taken together, our data indicate that HSVgdnf pretreatment provides protection against cerebral ischemia and supports the utilization of the HSV amplicon for therapeutic delivery of trophic factors to the CNS.",
keywords = "Amplicon, GDNF, Gene therapy, Herpes simplex, Ischemia, Stroke",
author = "Harvey, {B. K.} and Chang, {C. F.} and Chiang, {Y. H.} and Bowers, {W. J.} and M. Morales and Hoffer, {B. J.} and Y. Wang and Federoff, {H. J.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1016/S0014-4886(03)00080-3",
language = "English",
volume = "183",
pages = "47--55",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury

AU - Harvey, B. K.

AU - Chang, C. F.

AU - Chiang, Y. H.

AU - Bowers, W. J.

AU - Morales, M.

AU - Hoffer, B. J.

AU - Wang, Y.

AU - Federoff, H. J.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Direct intracerebral administration of glial cell line-derived neurotrophic factor (GDNF) is neuroprotective against ischemia-induced cerebral injury. Utilizing viral vectors to deliver and express therapeutic genes presents an opportunity to produce GDNF within localized regions of an evolving infarct. We investigated whether a herpes simplex virus (HSV) amplicon-based vector encoding GDNF (HSVgdnf) would protect neurons against ischemic injury. In primary cortical cultures HSVgdnf reduced oxidant-induced injury compared to the control vector HSVlac. To test protective effects in vivo, HSVgdnf or HSVlac was injected into the cerebral cortex 4 days prior to, or 3 days, after a 60-min unilateral occlusion of the middle cerebral artery. Control stroke animals developed bradykinesia and motor asymmetry; pretreatment with HSVgdnf significantly reduced such motor deficits. Animals receiving HSVlac or HSVgdnf after the ischemic insult did not exhibit any behavioral improvement. Histological analyses performed 1 month after stroke revealed a reduction in ischemic tissue loss in rats pretreated with HSVgdnf. Similarly, these animals exhibited less immunostaining for glial fibrillary acidic protein and the apoptotic marker caspase-3. Taken together, our data indicate that HSVgdnf pretreatment provides protection against cerebral ischemia and supports the utilization of the HSV amplicon for therapeutic delivery of trophic factors to the CNS.

AB - Direct intracerebral administration of glial cell line-derived neurotrophic factor (GDNF) is neuroprotective against ischemia-induced cerebral injury. Utilizing viral vectors to deliver and express therapeutic genes presents an opportunity to produce GDNF within localized regions of an evolving infarct. We investigated whether a herpes simplex virus (HSV) amplicon-based vector encoding GDNF (HSVgdnf) would protect neurons against ischemic injury. In primary cortical cultures HSVgdnf reduced oxidant-induced injury compared to the control vector HSVlac. To test protective effects in vivo, HSVgdnf or HSVlac was injected into the cerebral cortex 4 days prior to, or 3 days, after a 60-min unilateral occlusion of the middle cerebral artery. Control stroke animals developed bradykinesia and motor asymmetry; pretreatment with HSVgdnf significantly reduced such motor deficits. Animals receiving HSVlac or HSVgdnf after the ischemic insult did not exhibit any behavioral improvement. Histological analyses performed 1 month after stroke revealed a reduction in ischemic tissue loss in rats pretreated with HSVgdnf. Similarly, these animals exhibited less immunostaining for glial fibrillary acidic protein and the apoptotic marker caspase-3. Taken together, our data indicate that HSVgdnf pretreatment provides protection against cerebral ischemia and supports the utilization of the HSV amplicon for therapeutic delivery of trophic factors to the CNS.

KW - Amplicon

KW - GDNF

KW - Gene therapy

KW - Herpes simplex

KW - Ischemia

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0043192384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043192384&partnerID=8YFLogxK

U2 - 10.1016/S0014-4886(03)00080-3

DO - 10.1016/S0014-4886(03)00080-3

M3 - Article

VL - 183

SP - 47

EP - 55

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -